Literature DB >> 15140978

Porcine endogenous retrovirus transmission characteristics of galactose alpha1-3 galactose-deficient pig cells.

Gary Quinn1, James C Wood, David J J Ryan, Kristen M Suling, Kathleen M Moran, Donna L Kolber-Simonds, Julia L Greenstein, Henk-Jan Schuurman, Robert J Hawley, Clive Patience.   

Abstract

Galactose alpha1-3 galactose (Gal) trisaccharides are present on the surface of wild-type pig cells, as well as on viruses particles produced from such cells. The recognition of Gal sugars by natural anti-Gal antibodies (NAb) in human and Old World primate serum can cause the lysis of the particles via complement-dependent mechanisms and has therefore been proposed as an important antiviral mechanism. Recently, pigs have been generated that possess disrupted galactosyl-transferase (GGTA1) genes. The cells of these pigs do not express Gal sugars on their surface, i.e., are Gal null. Concerns have been raised that the risk of virus transmission from such pigs may be increased due to the absence of the Gal sugars. We investigated the sensitivity of porcine endogenous retrovirus (PERV) produced from Gal-null and Gal-positive pig cells to inactivation by purified NAb and human serum. PERV produced in Gal-null pig cells was resistant to inactivation by either NAb or human serum. In contrast, although Gal-positive PERV particles were sensitive to inactivation by NAb and human serum, they required markedly higher concentrations of NAb for inactivation compared to the Gal-positive cells from which they were produced. Complete inactivation of Gal-positive PERV particles was not achievable despite the use of high levels of NAb, indicating that NAb-mediated inactivation of cell-free PERV particles is an inefficient process.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15140978      PMCID: PMC415821          DOI: 10.1128/JVI.78.11.5805-5811.2004

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  32 in total

Review 1.  Implications of the advent of homozygous alpha l, 3-galactosyltransferase gene-deficient pigs on transmission of infectious agents.

Authors:  Louisa E Chapman; Carolyn A Wilson
Journal:  Xenotransplantation       Date:  2003-07       Impact factor: 3.907

Review 2.  The alpha-galactosyl epitope: a sugar coating that makes viruses and cells unpalatable.

Authors:  R P Rother; S P Squinto
Journal:  Cell       Date:  1996-07-26       Impact factor: 41.582

3.  Immortalized bone-marrow derived pig endothelial cells.

Authors:  J D Seebach; M K Schneider; C A Comrack; A LeGuern; S A Kolb; P A Knolle; S Germana; H DerSimonian; C LeGuern; D H Sachs
Journal:  Xenotransplantation       Date:  2001-02       Impact factor: 3.907

4.  Alteration of glycosylation renders HIV sensitive to inactivation by normal human serum.

Authors:  D J Reed; X Lin; T D Thomas; C W Birks; J Tang; R P Rother
Journal:  J Immunol       Date:  1997-11-01       Impact factor: 5.422

5.  High-titer packaging cells producing recombinant retroviruses resistant to human serum.

Authors:  F L Cosset; Y Takeuchi; J L Battini; R A Weiss; M K Collins
Journal:  J Virol       Date:  1995-12       Impact factor: 5.103

6.  Transgenic pigs and virus adaptation.

Authors:  R A Weiss
Journal:  Nature       Date:  1998-01-22       Impact factor: 49.962

7.  Production of alpha-1,3-galactosyltransferase knockout pigs by nuclear transfer cloning.

Authors:  Liangxue Lai; Donna Kolber-Simonds; Kwang-Wook Park; Hee-Tae Cheong; Julia L Greenstein; Gi-Sun Im; Melissa Samuel; Aaron Bonk; August Rieke; Billy N Day; Clifton N Murphy; David B Carter; Robert J Hawley; Randall S Prather
Journal:  Science       Date:  2002-01-03       Impact factor: 47.728

8.  Type C retrovirus released from porcine primary peripheral blood mononuclear cells infects human cells.

Authors:  C A Wilson; S Wong; J Muller; C E Davidson; T M Rose; P Burd
Journal:  J Virol       Date:  1998-04       Impact factor: 5.103

9.  Production of alpha 1,3-galactosyltransferase-deficient pigs.

Authors:  Carol J Phelps; Chihiro Koike; Todd D Vaught; Jeremy Boone; Kevin D Wells; Shu-Hung Chen; Suyapa Ball; Susan M Specht; Irina A Polejaeva; Jeff A Monahan; Pete M Jobst; Sugandha B Sharma; Ashley E Lamborn; Amy S Garst; Marilyn Moore; Anthony J Demetris; William A Rudert; Rita Bottino; Suzanne Bertera; Massimo Trucco; Thomas E Starzl; Yifan Dai; David L Ayares
Journal:  Science       Date:  2002-12-19       Impact factor: 47.728

10.  Identification of alpha-galactosyl and other carbohydrate epitopes that are bound by human anti-pig antibodies: relevance to discordant xenografting in man.

Authors:  D K Cooper; A H Good; E Koren; R Oriol; A J Malcolm; R M Ippolito; F A Neethling; Y Ye; E Romano; N Zuhdi
Journal:  Transpl Immunol       Date:  1993       Impact factor: 1.708

View more
  6 in total

1.  Herpes simplex virus type 1 and 2 glycoprotein C prevents complement-mediated neutralization induced by natural immunoglobulin M antibody.

Authors:  Lauren M Hook; John M Lubinski; Ming Jiang; Michael K Pangburn; Harvey M Friedman
Journal:  J Virol       Date:  2006-04       Impact factor: 5.103

Review 2.  Infection barriers to successful xenotransplantation focusing on porcine endogenous retroviruses.

Authors:  Joachim Denner; Ralf R Tönjes
Journal:  Clin Microbiol Rev       Date:  2012-04       Impact factor: 26.132

3.  Reduced sensitivity to human serum inactivation of enveloped viruses produced by pig cells transgenic for human CD55 or deficient for the galactosyl-alpha(1-3) galactosyl epitope.

Authors:  Saema Magre; Yasuhiro Takeuchi; Gillian Langford; Andrew Richards; Clive Patience; Robin Weiss
Journal:  J Virol       Date:  2004-06       Impact factor: 5.103

4.  Bortezomib, C1-inhibitor and plasma exchange do not prolong the survival of multi-transgenic GalT-KO pig kidney xenografts in baboons.

Authors:  S Le Bas-Bernardet; X Tillou; J Branchereau; N Dilek; N Poirier; M Châtelais; B Charreau; D Minault; J Hervouet; K Renaudin; C Crossan; L Scobie; Y Takeuchi; M Diswall; M E Breimer; N Klar; M R Daha; P Simioni; S C Robson; M B Nottle; E J Salvaris; P J Cowan; A J F d'Apice; D H Sachs; K Yamada; I Lagutina; R Duchi; A Perota; G Lazzari; C Galli; E Cozzi; J-P Soulillou; B Vanhove; G Blancho
Journal:  Am J Transplant       Date:  2015-02       Impact factor: 8.086

Review 5.  PERVading strategies and infectious risk for clinical xenotransplantation.

Authors:  Christopher G A McGregor; Yasu Takeuchi; Linda Scobie; Guerard Byrne
Journal:  Xenotransplantation       Date:  2018-07       Impact factor: 3.907

6.  A comprehensive microbiological safety approach for agarose encapsulated porcine islets intended for clinical trials.

Authors:  Lawrence S Gazda; James Collins; Archie Lovatt; Robert W Holdcraft; Merribeth J Morin; Daniel Galbraith; Melanie Graham; Melissa A Laramore; Christine Maclean; John Black; Euan W Milne; Douglas G Marthaler; Horatiu V Vinerean; Michelle M Michalak; Deborah Hoffer; Steven Richter; Richard D Hall; Barry H Smith
Journal:  Xenotransplantation       Date:  2016-11-11       Impact factor: 3.907

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.